natalizumab - rezultati iskanja

Evropska unija - slovenščina - EMA (European Medicines Agency)

natalizumab elan pharma

elan pharma international ltd. - natalizumab - crohnova bolezen - immunostimulants, - zdravljenje zmerno do hudo aktivno crohnovo boleznijo za zmanjšanje znakov in simptomov, in uvajanja in vzdrževanja trajno odziva in odpust, pri bolnikih, ki se niso odzvali, kljub temu polno in ustrezni tečaj zdravljenja s kortikosteroidi in immunosuppressant; ali ne prenašajo ali imajo medicinske kontraindikacije za take terapije.

Evropska unija - slovenščina - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Evropska unija - slovenščina - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalizumab - multiple skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Evropska unija - slovenščina - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimetil fumarat - multiplo sklerozo, recidivno-nakazila - imunosupresivi - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.